Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/04/03 02:42:46」(JST)
wiki en
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 早産児における呼吸窮迫症候群の予防および治療 prevention and treatment of respiratory distress syndrome in preterm infants
English Journal
- Medication Use in the Neonatal Intensive Care Unit.
- Hsieh EM1, Hornik CP2, Clark RH3, Laughon MM4, Benjamin DK Jr2, Smith PB2; on Behalf of the Best Pharmaceuticals for Children Act—Pediatric Trials Network.Author information 1Duke-National University of Singapore Graduate Medical School, Singapore.2Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina.3Pediatrix-Obstetrix Center for Research and Education, Sunrise, Florida.4Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina.AbstractObjective The aim of the article is to provide an update on medication use in infants admitted to the neonatal intensive care unit (NICU) in the United States and examine how use has changed over time. Study Design We performed a retrospective review (2005-2010) of a large prospectively collected administrative database. Result Medications most commonly administered during the study period were ampicillin, gentamicin, caffeine citrate, vancomycin, beractant, furosemide, fentanyl, dopamine, midazolam, and calfactant (56-681 exposures per 1,000 infants). Those with the greatest relative increase in use included azithromycin, sildenafil, and milrinone. Medications with the greatest relative decrease in use included theophylline, metoclopramide, and doxapram. Conclusion Medication use in the NICU has changed substantially over time, and only 35% of the most commonly prescribed medications are Food and Drug Administration -approved in infants.
- American journal of perinatology.Am J Perinatol.2013 Dec 17. [Epub ahead of print]
- Objective The aim of the article is to provide an update on medication use in infants admitted to the neonatal intensive care unit (NICU) in the United States and examine how use has changed over time. Study Design We performed a retrospective review (2005-2010) of a large prospectively collecte
- PMID 24347262
- Comparative effectiveness of surfactant preparations in premature infants.
- Trembath A1, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M; Best Pharmaceuticals for Children Act—Pediatric Trials Network.Collaborators (22)Benjamin DK Jr, Berezny K, Cohen-Wolkowiez M, Smith P, Barrett J, Wade K, Capparelli E, Kearns GL, Laughon M, Muelenaer A, O'Shea T, Paul IM, van den Anker J, Siegel D, Taylor-Zapata P, Zajicek A, Tsilou K, Pagan A, Anand R, Brandt D, Clemons T, Simone G.
- The Journal of pediatrics.J Pediatr.2013 Oct;163(4):955-60.e1. doi: 10.1016/j.jpeds.2013.04.053. Epub 2013 Jun 12.
- OBJECTIVE: To compare effectiveness of 3 surfactant preparations (beractant, calfactant, and poractant alfa) in premature infants for preventing 3 outcomes: (1) air leak syndromes; (2) death; and (3) bronchopulmonary dysplasia (BPD) or death (composite outcome).STUDY DESIGN: We conducted a comparati
- PMID 23769501
- The relationship of fluid administration to outcome in the pediatric calfactant in acute respiratory distress syndrome trial.
- Willson DF1, Thomas NJ, Tamburro R, Truemper E, Truwit J, Conaway M, Traul C, Egan EE; Pediatric Acute Lung and Sepsis Investigators Network.Collaborators (49)Chae-Man L, Loftis L, Kyle U, Wensley D, Krahn G, Festa M, Gorey E, Quasney M, Murkowski K, Poynter S, Monaco M, Stanley M, Biagas K, Talathoti N, Pon S, Correa C, Palmer A, Godshall A, Mattix C, Lev A, Arshed S, Dockery K, Huddleston K, McLaughlin G, Castelblanco A, Chase M, Guittar P, Truemper E, Zink M, Thomas N, Stokes J, Erickson S, Falconer P, Bysani K, Barclay T, Butt W, Delzoppo C, Stephens D, Thomas J, Beca J, Stapelton H, Jouvet P, Poitras N, Ten I, Lamb M, Willson D, Traul C, Yung M, Lyon C.
- Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.Pediatr Crit Care Med.2013 Sep;14(7):666-72. doi: 10.1097/PCC.0b013e3182917cb5.
- OBJECTIVES: Adult studies have demonstrated the relationship between fluid overload and poor outcomes in acute lung injury/acute respiratory distress syndrome. The approach of pediatric intensivists to fluid management in acute lung injury/acute respiratory distress syndrome and its effect on outcom
- PMID 23925143
Japanese Journal
- Effect of exogenous surfactant (calfactant) in pediatric acute lung injury : a randomized controlled trial
- WILLSON DF
- JAMA 293, 470-476, 2005
- NAID 30005376790
Related Links
- Calfactant, also known as Infasurf, is an intratracheal suspension derived from the natural surfactant in calf lungs. This lung surfactant is essential for effective ventilation as it modifies alveolar surface tension. Neonatal respiratory distress is ...
- 7 May 2009 ... Learn about the prescription medication Infasurf (Calfactant), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling.
Related Pictures
★リンクテーブル★
| リンク元 | 「肺表面活性物質」 |
「肺表面活性物質」
- 胎児のII型肺胞上皮細胞で在胎20週ころから産生され始め、在胎32週以降に急激に産生が増加する (PED.396) → 胎児#胎児の成長
- 胎児の肺は妊娠26週には構造が完成し、妊娠34週頃には肺のサーファクタント産生が十分量に達して機能的に成熟(G10M.144)
- 肺サーファクタントが羊水に出現するのは妊娠28-32週ごろ (出典不明)
米国
- Surfaxin(lucinactant)
- Survanta(beractant)
- Curosurf(poractantalpha)
- Infasurf(calfactant)